Since we showed that HP1-deficiency impaired homologous recombination repair and rendered BRCAness phenotype in breast cancer cells [17], we confirmed the cytotoxicity of PARP inhibitor for HP1-deficient breast cancer cells (Fig. 4). The gene discussed is PARP1; the disease is breast carcinoma.